ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,172.15
0.63%
Dow Jones
38,225.86
0.85%
Gold vs US Dollar
2,303.68
-0.89%
Brent Oil
83.605
0.08%
Bitcoin
59,223.31
1.69%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arvinas Inc (ARVN)

  7. Arvinas Inc (ARVN) News

Arvinas (ARVN)

Arvinas Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARVN
DateTimeSourceHeadlineSymbolCompany
02/05/202412:00GlobeNewswire Inc.Arvinas to Present at Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
24/04/202421:30GlobeNewswire Inc.Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerNASDAQ:ARVNArvinas Inc
11/04/202412:00GlobeNewswire Inc.Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerNASDAQ:ARVNArvinas Inc
18/03/202420:40GlobeNewswire Inc.Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerNASDAQ:ARVNArvinas Inc
04/03/202412:00GlobeNewswire Inc.Arvinas to Participate in Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
27/02/202423:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
27/02/202423:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
27/02/202423:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
27/02/202423:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
27/02/202421:46Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ARVNArvinas Inc
27/02/202412:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
27/02/202412:00GlobeNewswire Inc.Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
20/02/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
20/02/202421:05GlobeNewswire Inc.Arvinas Announces Chief Financial Officer TransitionNASDAQ:ARVNArvinas Inc
20/02/202412:00GlobeNewswire Inc.Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative DiseaseNASDAQ:ARVNArvinas Inc
14/02/202413:00GlobeNewswire Inc.Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast CancerNASDAQ:ARVNArvinas Inc
14/02/202401:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARVNArvinas Inc
06/02/202411:45GlobeNewswire Inc.Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast CancerNASDAQ:ARVNArvinas Inc
01/02/202421:30GlobeNewswire Inc.Arvinas to Present at 6th Annual Guggenheim Biotechnology ConferenceNASDAQ:ARVNArvinas Inc
16/01/202422:01GlobeNewswire Inc.Arvinas Appoints Jared Freedberg as General CounselNASDAQ:ARVNArvinas Inc
16/01/202421:03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ARVNArvinas Inc
08/01/202421:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
08/01/202412:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
08/12/202314:16Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:ARVNArvinas Inc
06/12/202312:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
06/12/202303:52GlobeNewswire Inc.Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development ProgramNASDAQ:ARVNArvinas Inc
05/12/202318:33GlobeNewswire Inc.Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development ProgramNASDAQ:ARVNArvinas Inc
28/11/202322:05GlobeNewswire Inc.Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer SymposiumNASDAQ:ARVNArvinas Inc
27/11/202312:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
27/11/202312:00GlobeNewswire Inc.Arvinas Announces Oversubscribed $350 Million Private PlacementNASDAQ:ARVNArvinas Inc
 Showing the most relevant articles for your search:NASDAQ:ARVN

Your Recent History

LSE
TERN
Tern
LSE
SCE
Surface Transforms
LSE
BIRD
Blackbird
LSE
AAU
Ariana Resources
LSE
IES
Invinity Energy Systems
LSE
SOLG
Solgold
LSE
POS
Plexus
LSE
SYME
Supply@me Capital
LSE
SCLP
Scancell
LSE
GKP
Gulf Keystone Petroleum
LSE
GFM
Griffin Mining
LSE
BT.A
Bt
LSE
PANR
Pantheon Resources
LSE
AAZ
Anglo Asian Mining
LSE
LLOY
Lloyds Banking
LSE
I3E
I3 Energy
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved